Hyperuricemia, urate-lowering therapy, and kidney outcomes: a systematic review and meta-analysis

Hyperuricemia, urate-lowering therapy, and kidney outcomes: a systematic review and meta-analysis

Background: Contradictory evidence exists for association of hyperuricemia and kidney function. To investigate the association of hyperuricemia and kidney function decline (hyperuricemia question) and effect of urate-lowering therapies (ULTs) on kidney function (ULT question), we performed a systema...

Full description

Bibliographic Details
Main Authors:	Gaurav Sharma, Abhishek Dubey, Nilesh Nolkha, Jasvinder A. Singh
Format:	Article
Language:	English
Published:	SAGE Publishing 2021-05-01
Series:	Therapeutic Advances in Musculoskeletal Disease
Online Access:	https://doi.org/10.1177/1759720X211016661

Similar Items

Chronic kidney disease: the role of hyperuricemia and the possibility of urate-lowering therapy
by: M. S. Eliseev
Published: (2018-04-01)

Effect of Urate-Lowering Therapy on the Progression of Kidney Function in Patients With Asymptomatic Hyperuricemia: A Systematic Review and Meta-Analysis
by: Lin Zhang, et al.
Published: (2022-01-01)

Comparative efcacy and safety of urate-lowering therapy for the treatment of hyperuricemia
Published: (2018-05-01)

Comorbidity in gout and hyperuricemia: prevalence, causes, prospects of urate lowering therapy
by: M S Eliseev, et al.
Published: (2019-05-01)

Impact of Hyperuricemia and Urate-Lowering Agents on Cardiovascular Diseases
by: Franklin Sosa, et al.
Published: (2024-03-01)

Advances in Urate Excretion and Urate Transporters in Hyperuricemia
by: XIN Jiadong, ZHOU Jiabao, WU Zhiyuan, ZHANG Xuming, GAO Jiandong
Published: (2023-05-01)

Hyperuricemia and Progression of Chronic Kidney Disease: A Review from Physiology and Pathogenesis to the Role of Urate-Lowering Therapy
by: Tao Han Lee, et al.
Published: (2021-09-01)

Bergenin as a Novel Urate-Lowering Therapeutic Strategy for Hyperuricemia
by: Mo Chen, et al.
Published: (2020-07-01)

Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials
by: Tunlanut Sapankaew, et al.
Published: (2022-06-01)

Urate-lowering agents for asymptomatic hyperuricemia in stage 3 - 4 chronic kidney disease: Controversial role of kidney function.
by: Hee Jung Jeon, et al.
Published: (2019-01-01)

Seasonal variations for newly prescribed urate-lowering drugs for asymptomatic hyperuricemia and gout in Japan
by: Masafumi Kurajoh, et al.
Published: (2024-01-01)

Urate-Lowering Agents in Asymptomatic Hyperuricemia: Role of Urine Sediment Analysis and Musculoskeletal Ultrasound
by: Davide Viggiano, et al.
Published: (2018-04-01)

Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study
by: Hiroshi Kataoka, et al.
Published: (2022-03-01)

Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
by: Aleš Kvasnička, et al.
Published: (2023-12-01)

Two cases of acute urate nephropathy in women with asymptomatic hyperuricemia
by: L. N. Yeliseyeva, et al.
Published: (2021-03-01)

Protective effects of Cyclocarya paliurus on hyperuricemia and urate-induced inflammation
by: Li-Hua Zhu, et al.
Published: (2022-07-01)

Urate-lowering therapy for heart failure
by: O. V. Zhelyabina, et al.
Published: (2019-09-01)

Urate-lowering therapy for gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database
by: Masataka Honda, et al.
Published: (2021-12-01)

Hyperuricemia causes kidney damage by promoting autophagy and NLRP3-mediated inflammation in rats with urate oxidase deficiency
by: Mian Wu, et al.
Published: (2021-03-01)

Hyperurikemia in chronic kidney disease stage 4 — the issue of suitability of urate-lowering therapy
by: I.I. Melnyk
Published: (2023-03-01)

Molecular Elucidation of a Urate Oxidase from <i>Deinococcus radiodurans</i> for Hyperuricemia and Gout Therapy
by: Yi-Chih Chiu, et al.
Published: (2021-05-01)

Research progress on related factors of pathogenicity of urate crystals in patients with asymptomatic hyperuricemia
by: Zhong Yang, Wang Lijuan, Wang Yuanli, Li Yasong
Published: (2022-02-01)

Gout - asymptomatic hyperuricemia with/without asymptomatic monosodium urate crystal deposition: To be treated or not?
by: Radak-Perović Marija, et al.
Published: (2019-01-01)

Effectiveness of Urate-Lowering Therapy for Renal Function in Patients With Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials
by: Xiuping Liang, et al.
Published: (2022-03-01)

Effects of uric acid-lowering therapy (ULT) on renal outcomes in CKD patients with asymptomatic hyperuricemia: a systematic review and meta-analysis
by: Yuxin Luo, et al.
Published: (2024-02-01)

Interventions to improve uptake of urate-lowering therapy in patients with gout: a systematic review
by: Iqbal Gill, et al.
Published: (2020-07-01)

Eggshell Membrane Ameliorates Hyperuricemia by Increasing Urate Excretion in Potassium Oxonate-Injected Rats
by: Yoon-Young Sung, et al.
Published: (2021-09-01)

Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
by: Emily E. Holladay, et al.
Published: (2024-04-01)

Rational use of recommendations for urate-lowering therapy: clinical examples
by: M. S. Eliseev, et al.
Published: (2022-06-01)

Engineered Escherichia coli Nissle 1917 with urate oxidase and an oxygen-recycling system for hyperuricemia treatment
by: Rui Zhao, et al.
Published: (2022-12-01)

Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout
by: Philip K. Tan, et al.
Published: (2017-04-01)

Behavioral Characteristics of Gout Patients and Their Impact on the Results of Urate Lowering Therapy
by: J. Chen, et al.
Published: (2021-04-01)

Prevention of arthritis attacks in the use of urate-lowering therapy in patients with gout
by: M. N. Chikina
Published: (2019-01-01)

Impact of urate-lowering therapy on quality of life indicators in patients with gout
by: M. N. Chikina, et al.
Published: (2021-06-01)

Oral Treatment With an Engineered Uricase, ALLN-346, Reduces Hyperuricemia, and Uricosuria in Urate Oxidase-Deficient Mice
by: Kateryna Pierzynowska, et al.
Published: (2020-11-01)

Konjac glucomannan improves hyperuricemia through regulating xanthine oxidase, adenosine deaminase and urate transporters in rats
by: Yuan Zhang, et al.
Published: (2018-09-01)

Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study
by: Matthew Roughley, et al.
Published: (2018-10-01)

Loss of the Kidney Urate Transporter, Urat1, Leads to Disrupted Redox Homeostasis in Mice
by: Neema Jamshidi, et al.
Published: (2023-03-01)

The association between hyperuricemia and the risk of acute kidney injury; a systematic review and meta-analysis
by: Mohammad Reza Rezaei, et al.
Published: (2023-06-01)

Febuxostat is superior to traditional urate-lowering agents in reducing the progression of kidney function in chronic kidney disease patients
by: Shuo-Chun Weng, et al.
Published: (2016-12-01)